INSILENS, A Noetera Company

Biotech Intelligence Platform

Turn Global Biotech Signals, Into Strategic Intelligence

Explore with us
Signal Overview
--
Total Signals
Indications Covered
--
Diseases
    Recent High-Impact Signals

      Top Signal This Week

      The single most consequential move in biotech right now — curated by the INSILENS desk.

      View all signals →
      Deals & Financing Novartis × Myricx Bio
      M&AADC

      Novartis Acquires Myricx Bio — Next-Generation ADC Payload Platform

      Novartis agreed to acquire Myricx Bio for up to $1.5B, including $1.1B upfront, adding a novel NMT-inhibitor ADC payload platform — a signal that big pharma is now paying premium value for payload architecture, not just late-stage clinical assets.

      INSILENS Desk July 6, 2026 4 min read

      Biotech Signals. Structured for Decisions.

      INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams.

      Deals and Financing
      Therapeutic Indication
      Technology Modalities
      View all

      Weekly Market Insight

      Nurix + Roche; Global BTK Degrader Collaboration
      ARPA-H Commits $160M to Personalized Gene Editing
      Merck – $1B Google AI Deal
      Incyte Acquires Vega Therapeutics